Corcept Therapeutics is expected to report a consensus revenue of $219.1 million and an EPS of $0.01, with the stock currently trading around $91.17 against a $92.17 analyst price target. Investors are primarily focused on the commercial launch trajectory of Lifyorli, which received early FDA approval in March 2026 for platinum-resistant ovarian cancer.
Management has guided for a return to profitability this quarter following a surprise Q1 loss driven by heavy Lifyorli launch expenses. Additionally, the market is awaiting updates on the June 17 NDA resubmission of relacorilant for Cushing’s syndrome, which remains a critical long-term growth driver for the company's cortisol modulation pipeline.